Patent intelligence · CA
CA 3262048
CX3CR1-BINDING COMPOUNDS, METHODS AND USES THEREOF
CX3CR1-BINDING COMPOUNDS, METHODS AND USES THEREOF
Patent details — CA 3262048
- Jurisdiction
- CA
- Status
- granted
- Grant date
- Jan 25, 2024
- Expiration
- Jan 20, 2044
- Applicant
- SANOFI SA [FR]
- CPC classes
- A61P/1100, A61P/1300, A61P/1900, A61P/2500
Quick answer
CA 3262048 (CX3CR1-BINDING COMPOUNDS, METHODS AND USES THEREOF) is held by SANOFI SA [FR]. Status: granted. Granted Jan 25, 2024. Expires Jan 20, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SANOFI SA [FR]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61P/1100, A61P/1300, A61P/1900, A61P/2500, A61P/2900, A61P/3500
More from SANOFI SA [FR]
Related pharmaceutical patents in our USPTO index.
-
WO 2026078159
AGENTS D'ACTIVATION DE CELLULES IMMUNITAIRES ET PROCÉDÉS LES COMPRENANT
granted -
WO 2026030375
NANOPARTICULES LIPIDIQUES ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
granted -
WO 2025262150
MOLÉCULES DE RECRUTEMENT D'ANTICORPS
granted -
AR 133055
DOMINIOS VARIABLES ÚNICOS DE INMUNOGLOBULINA DIRIGIDOS A PD-L1
granted -
MX 2025007399
PROTEIN-BASED CONJUGATION CARRIERS
granted -
WO 2025133166
VÉHICULES À BASE DE PROTÉINES POUR CONJUGAISON D'AMINE SPÉCIFIQUE À UN SITE
granted -
WO 2025133252
DOMAINES VARIABLES UNIQUES D'IMMUNOGLOBULINE CIBLANT CEACAM5
granted -
WO 2025133253
EXCIPIENTS DE CONJUGAISON PROTÉINIQUES POUR ADMINISTRATION INTRANUCLÉAIRE
granted
Frequently asked questions
What is US patent 3262048?
CA 3262048 (CX3CR1-BINDING COMPOUNDS, METHODS AND USES THEREOF) is held by SANOFI SA [FR]. Status: granted. Granted Jan 25, 2024. Expires Jan 20, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CA 3262048?
SANOFI SA [FR] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does CA 3262048 expire?
Our index shows an expiration date of Jan 20, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.